Laquinimod (LAQ) and interferon-β1a (IFN-β1a, Rebif) are immunomodulatory therapies for relapsing–remitting multiple sclerosis (RRMS) that may also influence vascular and hemostatic pathways. The gene discussed is IFNA1; the disease is relapsing-remitting multiple sclerosis.